In today's presentation I will give an overview to developing NextGen ADCs. We will discuss everything from the beginning stages of development to the varying ADC combination therapies available. (There are currently 23 ADCs in total being studied in 45 combination trials with 10 different immune checkpoint modulators).
Learning Objectives:
1. This presentation will discuss past, present challenges associated with developing antibody-drug conjugates (ADCs), a novel modality of targeted cancer chemotherapy
2. Presentation will also highlight key factors that influence in developing next generation ADCs.
Immunology
Cancer Research
Biotechnology
Oncology
Cancer Diagnostics
Laboratory Testing
Protein
Clinical Diagnostics
Cancer Therapeutics
Drug Discovery
Antibodies
Gene Sequencing
Cell Biology
Cancer
Dna Sequencing
North America33%
Asia33%
Europe33%
Website Visitors100%
Facility/Department Manager22%
Pharmacist11%
Student11%
Clinical Laboratory Scientist11%
Medical Doctor/Specialist11%
Educator/Faculty11%
Medical Laboratory Technician11%
Scientist11%
Academic Institution33%
Contract Research Organization (Cro)33%
Hospital22%
Manufacturer - Other11%